Get the Daily Brief
Latest Biotech News
3D gut‑brain‑vascular model exposes gut‑driven neuropathology
A team publishing in Nature Communications unveiled a 3D gut‑brain‑vascular platform that models bidirectional communication among gut, neural and vascular tissues. The system recapitulates...
Parkinson’s‑linked LRRK2R1627P mutation ramps gut inflammation — rat study ties to α‑synuclein
Researchers report that the LRRK2 R1627P mutation intensifies gut inflammation and accelerates α‑synuclein aggregation in rat models, linking a genetic Parkinson’s risk factor to early gut...
Nitazene deaths likely underreported by up to 33% — King’s College finds
A Clinical Toxicology study from King’s College London found that fatalities involving nitazene synthetic opioids may be undercounted by as much as one‑third, owing to limitations in toxicology...
Charles River and Thermo Fisher cut staff — site closures trigger layoffs
BioSpace’s layoff tracker reported workforce reductions at major contract research and laboratory services providers including Charles River and Thermo Fisher Scientific alongside site closures....
Hims halts compounded GLP‑1 program: Regulators close in
Hims & Hers stopped offering a compounded version of Novo Nordisk’s Wegovy after escalating federal pressure and legal threats. The company said it “decided to stop offering access” to the...
Roivant posts proof‑of‑concept win – Brepocitinib eyes pivotal testing
Priovant Therapeutics, a Roivant Sciences subsidiary, reported that brepocitinib—a dual JAK1/TYK2 inhibitor licensed from Pfizer—met endpoints in a proof‑of‑concept study in cutaneous sarcoidosis....
Sanofi unveils failed tolebrutinib data – PPMS program collapses
Sanofi disclosed detailed results from a failed Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS). The company’s presentation at ACTRIMS highlighted...
Phage plus antibiotic clears resistant peritonitis in preclinical model
Researchers reported in Nature Communications that combining bacteriophage therapy with antibiotics eradicated refractory Klebsiella pneumoniae peritonitis in a preclinical peritoneal dialysis...
Inflammasome protein ASC rewires pancreatic cancer metabolism
A Nature Communications study identified the inflammasome adaptor protein ASC as a central regulator linking innate immune signaling to mitochondrial metabolism in pancreatic cancer. Authors Chey,...
Succinate receptor SUCNR1 restrains hematopoiesis and limits AML
A Nature Communications paper showed that succinate receptor 1 (SUCNR1) functions as a metabolic sentinel that limits blood cell formation and suppresses acute myeloid leukemia progression. The...
Ferritin‑scaffold MERS spike vaccine shows potent responses
Researchers reported a stabilized MERS‑CoV spike protein presented on a ferritin nanoparticle induced robust immune responses in preclinical studies. The stabilized spike nanoparticle vaccine...
Dual targeting of viral and host pathways yields synergistic COVID activity
An Acta Pharmaceutica Sinica B study identified small‑molecule inhibitors of SARS‑CoV‑2 papain‑like protease (PLpro) and host kinase RIPK1 that, when combined, produced potent synergistic...
Bispecific siRNAs silence two oncogenic nodes at once
Nitto Denko reported a bispecific siRNA design that simultaneously knocks down YAP1 and WWTR1 (TAZ), two Hippo‑pathway effectors implicated in cancer. The Molecular Therapy — Nucleic Acids paper...
Eikon, Agomab pull $350M in IPOs — aftermarket punishes debut stocks
BioCentury reported that Eikon and Agomab raised $350 million combined in recent IPOs but saw share prices decline in the aftermarket. The public‑equity roundup highlighted uneven demand for...
Hims halts compounded Wegovy amid federal pressure
Hims & Hers stopped offering a compounded version of Novo Nordisk’s Wegovy after escalating legal pressure from federal regulators and calls for criminal review. The company said it “decided to...
PLpro and RIPK1 inhibitors synergize against SARS‑CoV‑2 in mice
Researchers reported that combining inhibitors targeting SARS‑CoV‑2 papain‑like protease (PLpro) with host RIPK1 inhibitors produced potent, synergistic antiviral effects in a mouse COVID‑19...
Brepocitinib clears proof‑of‑concept — Roivant advances to pivotal testing
A proof‑of‑concept study showed brepocitinib, a dual JAK1/TYK2 inhibitor licensed by Priovant (a Roivant subsidiary) from Pfizer, met endpoints in cutaneous sarcoidosis, a rare inflammatory skin...
Sanofi dissects failed tolebrutinib PPMS study — company retreats
Sanofi disclosed data from a failed Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS), an outcome that prompted the company to step back from the...
ARPA‑H trims commercialization staff amid restructure
ARPA‑H cut staff tied to commercialization and operations, according to multiple sources, shedding roles meant to move funded technologies toward market. The agency confirmed layoffs but said...
Biotech markets thaw: IPOs lift nearly $1bn as Series A steadies
Four drug companies went public this week—Agomab, Eikon, Spyglass and Veradermics—raising about $350m on IPO days and approaching nearly $1bn combined in recent public offerings, according to...